Center for Beta Cell Therapy in Diabetes ASBL
0.1 FTECenter for Beta Cell Therapy in Diabetes reported total assets of €3.16m at the end of the 2025 financial year (annual accounts filed with the NBB on 24 Jul 2026), with 0.1 full-time equivalent.
By total assets for 2025, Center for Beta Cell Therapy in Diabetes ranks among the 200 largest of the 993 companies in its sector (NACE 7210) in Belgium that filed accounts for that financial year. Largest companies in the sector →
The score of Center for Beta Cell Therapy in Diabetes shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity -12 % Total assets -3 % Headcount (avg FTE) -50 %
Accounts of the company itself (not consolidated).
The full file covers 8 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Center for Beta Cell Therapy in Diabetes's annual accounts
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net result | −219,285 € | ||||
| Equity | €2.62m | ||||
| Cash | 141,200 € | ||||
| EBITDA | −214,273 € | ||||
| Total assets | €3.16m |
Filed annual accounts
- Year ended 31 Dec 2025filed on 24 Jul 2026
- Year ended 31 Dec 2024filed on 23 Apr 2025
- Year ended 31 Dec 2023filed on 11 Jun 2024
- Year ended 31 Dec 2022filed on 10 May 2023
- Year ended 31 Dec 2021filed on 21 Apr 2022
Center for Beta Cell Therapy in Diabetes's financial analysis
- Solvency83.0%sector median: 45.7%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Center for Beta Cell Therapy in Diabetes
5 active director(s) in the register.
Center for Beta Cell Therapy in Diabetes's shareholders and holdings →Center for Beta Cell Therapy in Diabetes's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0872.566.468
- VAT number
- No VAT activity declared to the CBE
- Peppol
- Registered · 0208:0872566468 · as of 10 Nov 2026
- Legal form
- ASBL
- Incorporated
- 17 Mar 2005
- Registered office
- 1090 Jette
- Size
- Micro · 0.1 FTE
- Latest accounts
- 2025 · filed on 24 Jul 2026
- Activity
- Research and experimental development on other natural sciences and engineering (NACE 72109)
Center for Beta Cell Therapy in Diabetes (ASBL) has been based in Jette since 2005, active in: research and experimental development on other natural sciences and engineering. For 2025, it reports a net loss of 219,285 € and equity of €2.62m; its revenue is not published. With 0.1 full-time equivalents, it is a micro-enterprise by headcount. Its solvency stands at 83.0%, above the median of its sector (45.7%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to Center for Beta Cell Therapy in Diabetes
Companies in the same business, of comparable size and area, outside its group.
- Institut de Securite Incendie - Instituut voor Brandveiliging Research and experimental development on natural sciences and engineering Liège · balance sheet 342,047 €
- Centre Pilote wallon des Céréales et Oléo-protéagineux Research and experimental development on natural sciences and engineering Gembloux · balance sheet 843,824 €
- FeBelGen Research and experimental development on natural sciences and engineering Brussels · balance sheet €3.30m
- Data, AI and Robotics (DAIRO) Research and experimental development on natural sciences and engineering Brussels · balance sheet €2.99m
- Centre de Recherche,d'Etude et de Formation Continue de la HELHA Research and experimental development on natural sciences and engineering Mons · balance sheet €2.52m
- Belgisch Centrum voor Technologisch Onderzoek van Leidingen en Toebehoren Research and experimental development on natural sciences and engineering Merelbeke-Melle · balance sheet €5.05m
- CD3 Labs Research and experimental development on natural sciences and engineering Leuven · balance sheet €1.79m
- European Marine Board Research and experimental development on natural sciences and engineering Ostend · balance sheet €1.70m
Frequently asked questions about Center for Beta Cell Therapy in Diabetes
What is the revenue of Center for Beta Cell Therapy in Diabetes?
Center for Beta Cell Therapy in Diabetes files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Center for Beta Cell Therapy in Diabetes?
According to the Crossroads Bank for Enterprises, no VAT-liable activity is declared for Center for Beta Cell Therapy in Diabetes. If it is VAT-registered, its VAT number is its company number prefixed with BE: BE0872566468. Its company number (CBE) is 0872.566.468.
Where is the registered office of Center for Beta Cell Therapy in Diabetes?
According to the CBE register, the registered office of Center for Beta Cell Therapy in Diabetes is in 1090 Jette.
What is the equity of Center for Beta Cell Therapy in Diabetes?
At the close of the 2025 financial year, the equity of Center for Beta Cell Therapy in Diabetes amounts to 2,624,530 €, a solvency of 83.0% of total assets.
How many people work at Center for Beta Cell Therapy in Diabetes?
0.1 full-time equivalents on average according to the 2025 social balance sheet.
Who manages Center for Beta Cell Therapy in Diabetes?
The register lists 5 active mandates at Center for Beta Cell Therapy in Diabetes. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
How large is Center for Beta Cell Therapy in Diabetes within its sector?
By total assets for 2025, Center for Beta Cell Therapy in Diabetes ranks among the 200 largest of the 993 companies in its sector (NACE 7210) in Belgium that filed accounts for that financial year.
The full file of Center for Beta Cell Therapy in Diabetes
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →